Company intelligence / Profile preview
Nosis Biosciences
Berkeley, California, United Statesnosisbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead fibrosis program was nominated as a development candidate in July 2025 and is in IND-enabling studies as of Q3 2025; no clinical data has been reported yet. The company has preclinical programs for other indications and key partnerships for additional discovery-stage assets.[2][11]
- Therapeutic areas
- CardiovascularOtherNeurologyImmunology
- Modalities
- Small interfering RNAAntisense oligonucleotideProtein-drug conjugateRadiopharmaceuticalRNA therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Daiichi Sankyo (platform collaboration for cell-targeted RNA therapeutics development)[4][6][7]Johnson & Johnson (platform/drug discovery collaboration for cell-targeted RNA therapeutics)[6][8]
Beyond the preview
Go deeper on Nosis Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nosis Biosciences.